Carbimazole

ethyl 4-iodo-1H-pyrazole-3-carboxylate.

ethyl 4-iodo-1H-pyrazole-3-carboxylate.

ethyl 4-iodo-1H-pyrazole-3-carboxylate.

ethyl 4-iodo-1H-pyrazole-3-carboxylate.

Ethyl 5-propyl-1H-pyrazole-3-carboxylate.

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.

A synthetic intermediate useful for pharmaceutical synthesis.

FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC 50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma researchIn VivoFGFR4-IN-5 (oral gavage: 10 mg/kg: single dose)

FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC 50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma researchIn VivoFGFR4-IN-5 (oral gavage: 10 mg/kg: single dose)

FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC 50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma researchIn VivoFGFR4-IN-5 (oral gavage: 10 mg/kg: single dose)

InformationGDC-0575 (ARRY-575, RG7741) is a potent and selectiveCHK1inhibitor with an IC50 of 1.2 nM.In vitroGDC-0575 enhances the cytotoxicity of Cytarabine (AraC) in vitro.In vivoGDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor